Casdin Partners Master Fund, L.P., 10% Owner at Fulcrum Therapeutics, Inc. (FULC), bought 604,285 shares at $14.50 ($2.2M) on 2019-07-22, disclosed to the SEC on 2019-07-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 464,285 | $0 | 0.0% |
| 2 | $14.50 | 5,000 | $73K | 3.3% |
| 3 | $14.50 | 10,000 | $145K | 6.5% |
| 4 | $16.00 | 125,000 | $2.0M | 90.2% |
| Total | $3.67 avg | 604,285 | $2.2M | 100% |
| Filing → |
| LAB | BUY | 2025-09-11 | $129K | — | Filing → |
| LAB | BUY | 2025-08-26 | $658K | — | Filing → |
| WGS | BUY | 2024-03-06 | $358K | — | Filing → |